Original report · translated from Chinese
Innogen receives an emerging-company award in the 2026 China Enterprise Global Impact Annual Cases
On 13 June 2026, Jiemian Cailian hosted the China Enterprise Global Impact Dialogue in Shanghai and released its top-100 list. The selection assessed international capabilities across commercial value, international reputation and social responsibility. Innogen received an emerging-company award, which the company described as recognition of its original research and international strategy.
Innogen focuses on metabolic disease, internally developed medicines and international expansion, with a pipeline it describes as protected by global patents. Its programs address diabetes, obesity and metabolic fatty-liver disease, seeking to fill treatment gaps and bring Chinese innovation to international markets. The article describes core product efsubaglutide alfa as China’s first original humanised long-acting GLP-1 receptor agonist, challenging the long-standing dominance of overseas companies. It is approved for type 2 diabetes in the Chinese mainland and Macao, China, and is included in the National Reimbursement Drug List.
Research stage of hydrogel dosing intervals
Dosing every three to six months is a research goal. The related Theranostics study tested the approach in rodents and did not establish a dosing schedule for people.
The company continues to build its international presence. It is conducting a Phase II obesity study in Australia and developing longer-acting dosing approaches every two weeks (Q2W) and every four weeks (Q4W). Chinese Phase IIb overweight/obesity findings were presented at ADA, where the company reports that the duration of action and weight-loss results attracted international interest. Its internally developed hydrogel platform also supports research into dosing intervals of three to six months, intended to strengthen future competitiveness.
Chinese businesses’ international expansion increasingly integrates supply-chain planning, technology transfer and local operations. Biopharmaceuticals, combining advanced science and manufacturing, have become an important vehicle for that expansion. A Jiemian Cailian report identifies life sciences and biopharmaceuticals among four leading international-growth sectors, with innovative technology companies playing a central role. Innogen intends to follow global health-industry developments and patient needs, using scientific innovation to support high-quality international development across research, clinical work and commercialisation.
Note: Efsubaglutide alfa’s currently approved indication is type 2 diabetes. Obesity and weight-loss indications remain under clinical investigation and have not received marketing approval. This content communicates company research developments and industry information; it is not a pharmaceutical advertisement, treatment recommendation or promise of efficacy. Prescription medicines should be purchased with a physician’s prescription and used under medical supervision.
About Innogen
Founded in 2014, Innogen (HK.2591) is a biopharmaceutical company focused on developing and commercialising innovative medicines for metabolic diseases. Its internally developed pipeline covers indications including type 1 diabetes (T1D), obesity, metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer’s disease (AD), with international intellectual-property rights and a global patent strategy. Its core product, efsubaglutide alfa, is an internally developed, next-generation human-derived ultra-long-acting GLP-1 receptor agonist approved for type 2 diabetes in the Chinese mainland and Macao, China. It is included in the National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List (2025). The product has entered international development and registration, with the aim of providing better treatment options to patients worldwide. For more information, visit www.innogenpharm.com.